MedImmune for sale
Executive Summary
The biotechnology firm announces April 12 that it is exploring a possible sale. MedImmune has a market capitalization of over $10 billion and markets the influenza vaccine FluMist, the respiratory syncytial virus treatment Synagis (palivizumab) and the cytoprotective agent Ethyol (amifostine). A BLA for the Synagis follow-on Numax is planned for this year. The firm already has relationships with Merck and GlaxoSmithKline, which use the firm's "virus-like particle technology" in the production of HPV vaccines Gardasil and Cervarix. Pfizer has also expressed an interest in significantly boosting its biologics portfolio via acquisition...
You may also be interested in...
Astra Wins MedImmune Auction; $15.6 Billion Price Tag Raises Eyebrows
AstraZeneca's move to bolster its biologics portfolio through the acquisition of MedImmune for roughly $15.6 billion illustrates the increasingly high stakes of mergers in the biotech space
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.